Earlier this month, the JMF team traveled to New Orleans for the Clinical Immunology Society (CIS) Annual Meeting, bringing together physicians, scientists, advocates, patients, and families from around the world to advance the future of clinical #immunology. During the meeting, JMF Scientific Director Jessica Quinn presented a poster highlighting findings from an upcoming publication on the Jeffrey’s Insights genetic sequencing program. We were proud to see our WINMD Grant recipients attending and presenting research posters at CIS. Supporting the next generation of researchers and innovators in immunology remains a vital part of JMF’s mission. While in New Orleans, we also hosted an in-person meeting of our Patient & Family Advisory Board (#PFAB), uniting patients and families affected by STAT1 GOF, STAT3 GOF, and JAK1 GOF to help create educational resources that truly reflect and amplify the patient experience. We are honored to continue supporting collaboration, research, education, and patient advocacy within the global PI community 💙 #CIS2026 #ClinicalImmunology #PrimaryImmunodeficiency #PICommunity #RareDisease #PatientAdvocacy #NOLA #JMFPFAB

A major step forward for the Primary Immunodeficiency community 💙 The U.S. Food and Drug Administration has approved a new gene therapy for Wiskott-Aldrich syndrome – offering a potentially long-lasting treatment that uses a patient’s own cells to help restore immune function. For patients and families, this represents more than just scientific progress – it’s hope for safer, more effective care and a future with fewer infections and complications. Advances like this highlight the power of research, innovation, and advocacy in changing lives. Read the press release here: bit.ly/42cMqyH #PrimaryImmunodeficiency #PIAwareness #GeneTherapy #FDAApproval #Immunology #MedicalInnovation